References
- Ledermann JA , RajaFA, FotopoulouAet al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up. Ann. Oncol.24(6), 24–32 (2013).
- Bray F , FerlayJ, SoerjomataramIet al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.68(6), 394–424 (2018).
- Reid BM , PermuthJB, SellersTA. Epidemiology of ovarian cancer: a review. Cancer Biol. Med.14(1), 9–32 (2017).
- Siegel R , MillerK, JemalA. Cancer statistics 2017. CA Cancer J. Clin.67(1), 7–30 (2017).
- Ferlay J , SoerjomataramI, DikshitRet al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer136, E359–E386 (2015).
- Oronsky B , RayCM, SpiraAIet al. A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer. Med. Oncol.34, 103 (2017).
- Kiselev VI , AshrafyanLA, MuyzhnekELet al. A new promising way of maintenance therapy in advanced ovarian cancer: a comparative clinical study. BMC Cancer18, 904 (2018).
- Pharma Intelligence . FDA finally approves Avastin in first-line ovarian cancer (2019). https://pharmaintelligence.informa.com/resources/product-content/fda-finally-approves-avastin-in-first-line-ovarian-cancer
- European Medicines Agency . Annexe 10 to the annual report of the European Medicines Agency (2019). www.ema.europa.eu/en/documents/annual-report/annexes-annual-report-european-medicines-agency-2014_en.pdf
- Kim G , IsonG, McKeeAEet al. FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin. Cancer Res.21, 4257–4261 (2015).
- European Medicines Agency . Rubraca (rucaparib) (2019). www.ema.europa.eu/en/medicines/human/EPAR/rubraca
- Food and Drug Administration . Rucaparib (2019). www.fda.gov/drugs/resources-information-approved-drugs/rucaparib
- European Medicines Agency . Zejula (niraparib) (2018). www.ema.europa.eu/en/medicines/human/EPAR/zejula
- Food and Drug Administration . Niraparib (2019). www.fda.gov/drugs/resources-information-approved-drugs/niraparib-zejula
- Miksad RA , AbernethyAP. Harnessing the power of real-world evidence (RWE): a checklist to ensure regulatory-grade data quality. Clin. Pharmacol. Ther.103(2), 202–205 (2018).
- Anderson P , BenfordM, HarrisNet al. Real-world physician and patient behaviour across countries: disease specific programmes – a means to understand. Curr. Med. Res. Opin.24, 3063–3072 (2008).
- Western IRB (WIRB) . WIRB study number: 1180976, protocol number: 20172679 (2018). www.wirb.com
- European Pharmaceutical Market Research Association (EphMRA) . European Pharmaceutical Market Research Association (EphMRA) Code of Conduct Updated January 2017 (2018). www.ephmra.org/Code-of-Conduct-Support
- US Department of Health and Human Services . Summary of the HIPAA Privacy Rule; 2003 (2018). www.hhs.gov/sites/default/files/privacysummary.pdf
- Health Information Technology . Health information technology act (2018). www.healthit.gov/sites/default/files/hitech_act_excerpt_from_arra_with_index.pdf.
- Rosner B . Fundamentals of Biostatistics (8th Edition). Chapter 2: Descriptive Statistics, Cengage Learning, MA, USA (2016).
- Cohen J . A coefficient of agreement for nominal scales. Educ. Psychol. Meas.20, 37–46 (1960).
- Viera AJ , GarrettJM. Understanding interobserver agreement: the kappa statistic. Fam. Med.37, 360–363 (2005).
- Doubeni CA , DoubeniAR, MyersAE. Diagnosis and management of ovarian cancer. Am. Fam. Physician93(11), 937–944 (2016).
- Moore RG , MacLaughlanS, BastRCJr. Current state of biomarker development for clinical application in epithelial ovarian cancer. Gynecol. Oncol.116(2), 240–245 (2010).
- Koczkowska M , ZukM, GorczynskiAet al. Detection of somatic BRCA1/2 mutations in ovarian cancer – next-generation sequencing analysis of 100 cases. Cancer Med.5(7), 1640–1646 (2016).
- Kehoe S , HookJ, NankivellMet al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet386(9990), 249–257 (2015).
- Rossi L , VerricoM, ZaccarelliEet al. Bevacizumab in ovarian cancer: a critical review of Phase III studies. Oncotarget8(7), 12389–12405 (2017).
- Li J , ZhouL, ChenX, BaY. Addition of bevacizumab to chemotherapy in patients with ovarian cancer: a systematic review and meta-analysis of randomized trials. Clin. Transl. Oncol.17(9), 673–683 (2015).
- Wu YS , ShuiL, ShenD, ChenX. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials. Oncotarget8(6), 10703–10713 (2017).
- Di Silvestro P , AlvarezSecord A. Maintenance treatment of recurrent ovarian cancer: is it ready for prime time?Cancer Treat. Rev.69, 53–65 (2018).
- Previs RA , SecordAA. Ovarian cancer: clinical trial breakthroughs and impact on management. Obstet. Gynecol. Clin. North Am.46, 67–88 (2019).
- Cortez AJ , TudrejP, KujawaKA, LisowskaKM. Advances in ovarian cancer therapy. Cancer Chemother. Pharmacol.81, 17–38 (2018).
- Nekolaichuk CL , BrueraE, SpachynskiKet al. A comparison of patient and proxy symptom assessments in advanced cancer patients. Palliat. Med.13(4), 311–323 (1999).
- Sztankay M , GiesingerJM, ZaberniggAet al. Clinical decision-making and health-related quality of life during first-line and maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC): findings from a real-world setting. BMC Cancer17(1), 565 (2017).
- Donovan HS , HaganTL, CampbellGBet al. Nausea as a sentinel symptom for cytotoxic chemotherapy effects on the gut-brain axis among women receiving treatment for recurrent ovarian cancer: an exploratory analysis. Support. Care Cancer24(6), 2635–2642 (2016).
- Boyd LR , MuggiaFM. Carboplatin/paclitaxel induction in ovarian cancer: the finer points. Oncology (Williston Park)32(8), 418–20; 422–424 (2018).
- Saunders C , ByrneCD, GuthrieBet al. Scottish Diabetes Research Network Epidemiology Group. External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants? Diabet. Med. 30(3), 300–308 (2013).
- Hubbard TE , ParadisR. Real-world evidence: a new era for health care innovation. the network for excellence in health innovation (2015). www.nehi.net/writable/publication_files/file/rwe_issue_brief_final.pdf
- Battisti WP , WagnerE, BaltzerLet al. Good publication practice for communicating company-sponsored medical research: GPP3. Ann. Intern. Med.163(6), 461–464 (2015).